Expert perspectives on cholangiocarcinoma (CCA)

Multidisciplinary care: The role of the surgeon in cholangiocarcinoma (ILCA 2022)

Professor Thomas Gruenberger

HPB Center, Clinic Favoriten, Health Network Vienna,
Vienna, Austria

Cholangiocarcinoma: A rare cancer? (ILCA 2022)

Professor Jesús Bañales

Biodonostia Research Health Institute, Donostia-San Sebastián, Spain

Molecular profiling: Challenges and opportunities in cholangiocarcinoma (ILCA 2022)

Dr Teresa Macarulla

Vall d’Hebron University Hospital,
Barcelona, Spain

Panel discussion / Q&A (ILCA 2022)

Professor Jesús Bañales

Biodonostia Research Health Institute, Donostia-San Sebastián, Spain

Professor Thomas Gruenberger

HPB Center, Clinic Favoriten, Health Network Vienna,
Vienna, Austria

Dr Teresa Macarulla

Vall d’Hebron University Hospital,
Barcelona, Spain

Professor Bruno Sangro

Clinica Universidad de Navarra, Pamplona, Spain

Professor Harpreet Wasan

Hammersmith Hospital,
Imperial College London, London, UK

Exploring molecular pathways in cholangiocarcinoma: Implications for pathologists (ECP 2022)

Professor Aldo Scarpa

University of Verona
Verona, Italy

Advances in molecular profiling techniques for cholangiocarcinoma (ECP 2022)

Dr Daniel Kazdal

Centre for Molecular Pathology,
University Hospital Heidelberg,
Heidelberg, Germany

Biopsy collection in cholangiocarcinoma: Current status and future perspectives (ECP 2022)

Dr Ana Vivancos

Vall d’Hebron Institute of Oncology,
Barcelona, Spain

Panel discussion / Q&A (ECP 2022)

Professor Aldo Scarpa

University of Verona
Verona, Italy

Dr Daniel Kazdal

Centre for Molecular Pathology,
University Hospital Heidelberg,
Heidelberg, Germany

Dr Ana Vivancos

Vall d’Hebron Institute of Oncology,
Barcelona, Spain

Cholangiocarcinoma: The little-known, rare cancer of the biliary tract (ESMO 2022)

Professor Filippo de Braud

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Università degli Studi di Milano, Milan, Italy

The challenges associated with diagnosing intrahepatic cholangiocarcinoma for targeted therapies (ESMO 2022)

Professor Juan Valle

University of Manchester & The Christie, Manchester, UK

Optimising molecular profiling and the multidisciplinary team approach in cholangiocarcinoma (ESMO 2022)

Dr Angela Lamarca

Fundación Jiménez Díaz University Hospital, Spain

Overcoming diagnostic challenges associated with cholangiocarcinoma (ESMO GI 2022)

Professor Lorenza Rimassa

Associate Professor of Medical Oncology, Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy

Optimising molecular profiling in cholangiocarcinoma (ESMO GI 2022)

Professor John Bridgewater

Clinical Professor, University College London Cancer Institute, London, UK

Detecting FGFR2 fusions in patients with cholangiocarcinoma (ESMO GI 2021)

Dr Nicola Normanno

Istituto Nazionale per lo Studio e la Cura dei Tumori. Fondazione G. Pascale, Italy

Optimising the multidisciplinary team for cholangiocarcinoma management (ESMO 2021)

Dr David Malka

Department of Medical Oncology, Institut Mutualiste Montsouris, Paris, France
INSERM U1279, Villejuif, Université Paris-Saclay, France

When could “cancer of unknown primary” be cholangiocarcinoma? (ESMO 2021)

Professor Juan Valle

University of Manchester & The Christie, Manchester, UK

Importance of biomarkers in cholangiocarcinoma (ESMO GI 2021)

Dr Angela Lamarca

Fundación Jiménez Díaz University Hospital, Spain

Panel discussion / Q&A (ESMO 2022)

Professor Juan Valle

University of Manchester & The Christie, Manchester, UK

Dr David Malka

Department of Medical Oncology, Institut Mutualiste Montsouris, Paris, France
INSERM U1279, Villejuif, Université Paris-Saclay, France

Dr Antoine Hollebecque

Gustave Roussy, Villejuif, France

Dr Angela Lamarca

Fundación Jiménez Díaz University Hospital, Spain

Professor Filippo de Braud

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Università degli Studi di Milano, Milan, Italy

Panel discussion / Q&A (ESMO GI 2022)

Professor Arndt Vogel

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany

Professor John Bridgewater

Clinical Professor, University College London Cancer Institute, London, UK

Professor Lorenza Rimassa

Associate Professor of Medical Oncology, Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy

Professor Eric Van Cutsem

University Hospitals Gasthuisberg Leuven and
KU Leuven, Belgium

Company/Organisation	Relationship(s)
Albireo Pharma, CIMABay, Ikan Biotech, OWL Metabolomics, QED Therapeutics	Consulting/advisory role
Incyte, Intercept	Honoraria/lectures
Albireo, Incyte, Roche	Research funding

Company/Organisation	Relationship(s)
Albireo Pharma, CIMABay, Ikan Biotech, OWL Metabolomics, QED Therapeutics	Consulting/advisory role
Incyte, Intercept	Honoraria/lectures
Albireo, Incyte, Roche	Research funding

Company/Organisation	Relationship(s)
Adaptimmune, AstraZeneca, Bayer, Bristol Myers Squibb, Boston Scientific, Eisai, Exelixis, Ipsen, Lilly, Merck, Novartis, Roche, Sirtex Medical, Terumo	Consulting, advisory role or honoraria
Bristol Myers Squibb, Sirtex Medical	Grants

Company/Organisation	Relationship(s)
Array BioPharma, Bayer, Celgene, ERYTECH, Incyte, Pfizer, Pierre Fabre, Roche AG/Genentech/FM, SIRTEX Medical, Servier, Shire, Zymeworks	Advisory board
Celgene, NICE (uncompensated) expert for Bayer & Pierre Fabre, Oaktree capital, ONCOSIL, SIRTEX Medical	Consultancy
BMS, BTG/Biocompatibles, Merck KGaA	Honoraria/speaker/travel expenses
ERYTECH, Merck KGaA, Pfizer/Array, Zymeworks	Trials steering committee
BRC-Imperial, CRUK, Merck Serono, MRC, MSD, Pfizer, Sirtex Medical, UK NIHR	Research funding

Company/Organisation	Relationship(s)
Consulting/advisory role	Amgen, AstraZeneca, Basilea, Incyte, Ipsen
Honoraria/lectures	Amgen, GSK, Incyte, Merck, MSD, Sanofi, Roche, Serono

Company/Organisation	Relationship(s)
AstraZeneca, BMS, EMD Serono, Incyte, Menarini, MSD, Nerviano Medical Science, Novartis, Pierre Fabre, Roche, Sanofi	Consultant/advisory board
Amgen, BMS, Dephaforum, Healthcare Research & Pharmacoepidemiology, Incyte, Merck KGAA, MSD, Pfizer, Roche, Sanofi, Seagen, Servier	Speaker
Basilea Pharmaceutica International AG, BMS, Daiichi Sankyo, Exelixis, Roche, Ignyta Operating, Janssen, Kymab, LOXO Oncology, MedImmune, Merck KGAA, Merck Sharp & Dohme Italia Spa, MSD, Novartis, Pfizer, Tesaro	Principal investigator

Company/Organisation	Relationship(s)
Imaging Equipment Ltd, Ipsen, Novartis, NuCana	Speakers bureau
Celgene, NuCana	Travel grant
Agios, AstraZeneca, Debiopharm, Delcath Systems, GenoScience Pharma, Imaging Equipment Ltd, Incyte, Ipsen, Keocyt, Merck, Mundipharma EDO, Novartis, NuCana, PCI Biotech, Pieris Pharmaceuticals, Pfizer, QED, Servier, Wren Laboratories	Grant support

Company/Organisation	Relationship(s)
Albireo Pharma, AstraZeneca, Boehringer Ingelheim, Boston Scientific, Eisai, GenFit, Nutricia Ipsen, QED, Roche, Servier and TransThera Biosciences	Receipt of honoraria or consultation fees
AAA, AstraZeneca, Eisai, Incyte, Ipsen, Merck, Pfizer, QED, Roche and Servier	Participation in company-sponsored speaker bureau
AAA, Bayer, Delcath, Ipsen, Mylan, Novartis, Pfizer and Sirtex	Travel, education funding
Ipsen and Roche	Research funding

Company/Organisation	Relationship(s)
Amgen, ArQule, AstraZeneca, Basilea, Bayer, BMS, Celgene, Eisai, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, Lilly, MSD, Nerviano Medical Sciences, Roche, Sanofi, Servier, Taiho Oncology, Zymeworks	Consulting/Advisory role
AbbVie, Amgen, Bayer, Eisai, Gilead, Incyte, Ipsen, Lilly, Merck Serono, Roche, Sanofi, Servier	Honoraria/Lectures
AstraZeneca	Travel expenses
Agios, ARMO BioSciences, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, Zymeworks	Research funding to institution

Company/Organisation	Relationship(s)
MSD, Qiagen, Bayer, Biocartis, Illumina, Incyte, Roche, BMS, Merck, Thermo Fisher, Boehringer Ingelheim, AstraZeneca, Sanofi, Eli Lilly	Personal financial interests (speaker’s fee and/or advisory boards)
Merck, Sysmex, Thermo Fisher, QIAGEN, Roche, AstraZeneca, Biocartis, Illumina	Institutional financial interests (financial support to research projects)
President, International Quality Network for Pathology (IQN Path); President, Italian Cancer Society (SIC)	Non-financial interests

Company/Organisation	Relationship(s)
AbbVie, Agios, Amgen, AstraZeneca, Bayer, BMS, HalioDx, Incyte, Merck Serono, MSD, Pierre Fabre Oncologie, Roche, Sanofi, Servier, Taiho	Consulting/advisory role
Amgen, AstraZeneca, Bayer, BMS, Foundation Medicine, HalioDx, Incyte, Leo Pharma, Merck Serono, MSD, Pierre Fabre Oncologie, Roche, Sanofi, Servier, Veracyte, Viatris	Honoraria for lectures
Medscape	Personal fees for a writing engagement
Travel expenses	Amgen, Bayer, BMS, Merck Serono, MSD, Pierre Fabre Oncologie, Roche, Sanofi, Servier, Viatris

Company/Organisation	Relationship(s)
AstraZeneca, Bayer, Bristol-Myers Squibb, BTG, Daiichi-Sankyo, Eisai, GSK, Imaging Equipment Ltd (AAA), Incyte, Ipsen, Lilly, Merck, MSD, Pierre Fabre, Roche, Sanofi, Servier, Sirtex Medical, Terumo	Speaker/consulting/advisory role
Servier	Research funding
OncLive	Commercial medical education provider

Company/Organisation	Relationship(s)
Incyte	Consultant
Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, Servier	Research grants
Array, Astellas, AstraZeneca, Bayer, Beigene, Biocartis, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Daiichi, Halozyme, GSK, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Pierre Fabre, Roche, Servier, Sirtex Medical, Taiho	Advisory boards

Expert perspectives on cholangiocarcinoma (CCA)

Multidisciplinary care: The role of the surgeon in cholangiocarcinoma (ILCA 2022)

Cholangiocarcinoma: A rare cancer? (ILCA 2022)

Molecular profiling: Challenges and opportunities in cholangiocarcinoma (ILCA 2022)

Panel discussion / Q&A (ILCA 2022)

Exploring molecular pathways in cholangiocarcinoma: Implications for pathologists (ECP 2022)

Advances in molecular profiling techniques for cholangiocarcinoma (ECP 2022)

Biopsy collection in cholangiocarcinoma: Current status and future perspectives (ECP 2022)

Panel discussion / Q&A (ECP 2022)

Cholangiocarcinoma: The little-known, rare cancer of the biliary tract (ESMO 2022)

The challenges associated with diagnosing intrahepatic cholangiocarcinoma for targeted therapies (ESMO 2022)

Optimising molecular profiling and the multidisciplinary team approach in cholangiocarcinoma (ESMO 2022)

Overcoming diagnostic challenges associated with cholangiocarcinoma (ESMO GI 2022)

Optimising molecular profiling in cholangiocarcinoma (ESMO GI 2022)

Detecting FGFR2 fusions in patients with cholangiocarcinoma (ESMO GI 2021)

Optimising the multidisciplinary team for cholangiocarcinoma management (ESMO 2021)

When could “cancer of unknown primary” be cholangiocarcinoma? (ESMO 2021)

Importance of biomarkers in cholangiocarcinoma (ESMO GI 2021)

Panel discussion / Q&A (ESMO 2022)

Panel discussion / Q&A (ESMO GI 2022)

All videos in this category

Multidisciplinary care: The role of the surgeon in cholangiocarcinoma (ILCA 2022)

Cholangiocarcinoma: A rare cancer? (ILCA 2022)

Molecular profiling: Challenges and opportunities in cholangiocarcinoma (ILCA 2022)

Panel discussion / Q&A (ILCA 2022)

Exploring molecular pathways in cholangiocarcinoma: Implications for pathologists (ECP 2022)

Advances in molecular profiling techniques for cholangiocarcinoma (ECP 2022)

Biopsy collection in cholangiocarcinoma: Current status and future perspectives (ECP 2022)

Panel discussion / Q&A (ECP 2022)

Cholangiocarcinoma: The little-known, rare cancer of the biliary tract (ESMO 2022)

The challenges associated with diagnosing intrahepatic cholangiocarcinoma for targeted therapies (ESMO 2022)

Optimising molecular profiling and the multidisciplinary team approach in cholangiocarcinoma (ESMO 2022)

Overcoming diagnostic challenges associated with cholangiocarcinoma (ESMO GI 2022)

Optimising molecular profiling in cholangiocarcinoma (ESMO GI 2022)

Detecting FGFR2 fusions in patients with cholangiocarcinoma (ESMO GI 2021)

Optimising the multidisciplinary team for cholangiocarcinoma management (ESMO 2021)

When could “cancer of unknown primary” be cholangiocarcinoma? (ESMO 2021)

Importance of biomarkers in cholangiocarcinoma (ESMO GI 2021)

Panel discussion / Q&A (ESMO 2022)

Panel discussion / Q&A (ESMO GI 2022)